CTMX FY 2014 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$827M

FY 2014 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+471.7% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$30M-586.3% margin

Net Income

-$30M-597.0% margin

EPS (Diluted)

$-0.87

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$30M

Stock-Based Comp.

$553,000

Balance Sheet

Total Assets

$73M

Total Liabilities

$152M

Stockholders' Equity

-$79M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$888,000	+471.7%
Gross Profit	$5M	$888,000	+471.7%
Operating Income	-$30M	-$15M	-99.0%
Net Income	-$30M	-$15M	-100.2%